Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page. If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet. FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted. The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.Traditionally, the holidays are for spending time with family and friends, perhaps with a varying degree of religious rituals or practices. There's also pressure not to miss certain family celebrations, but there will be times you can't make it – whether by choice or circumstance. So, if you're spending the holidays alone this year, you're actually not alone in wondering if it's OK to be alone. You hold the ticket to your happiness, even if you're spending the holidays (or any special day of the year) in a less conventional way—all by yourself. There's no correct formula for how to spend the holidays, experts say, and keeping that in mind is key when you're not going to be around your loved ones. Spending the holidays alone can feel lonely or empty, but it doesn't have to be that way. Loneliness is an issue during the winter holidays for many students and other clients, according to Diana Winston, director of UCLA Mindful , the mindfulness education center at UCLA Health. Not having people to spend the days with, "can compound any existing loneliness and worsen it during the holiday times," Winston said. New York psychologist Dr. Bryant Williams agreed, noting that being alone during the holidays "accentuates existing problems." Both experts suggest taking action to strengthen your mindset and fill your days with activities that you know nurture you. Go on a hike, take a walk in a park, visit the beach or engage in nature in a way that suits your lifestyle and location. Get out into "whatever nature you have available to you," Winston said, highlighting the importance of seizing opportunities to be outdoors. The benefits of simply being outside and surrounding yourself with nature are plenty, and why not rack up those benefits when you're spending the day or week alone? In the practice of forest bathing, one spends time in nature through activities like a walk or sitting and enjoying the environment, Dr. Leana Wen previously told CNN. "Forest therapy" can lower anxiety, improve mood and reduce blood pressure, studies show . You can simply take a walk, and make the most of that walk. A higher daily step count is linked to fewer depressive symptoms, according to a recent study in the journal JAMA Network Open. And it's not an impossible number—even 7,000 steps can lead to better mental health, said clinical psychologist Dr. Karmel Choi, who previously spoke to CNN. You don't have to miss out on all the fun just because you can't be there to celebrate in person. Williams recommended people take action to reach out to people with a phone or video call. Do something "similar to what people did during the pandemic, when people were so isolated," he said. "People, because they weren't spending time with each other in person, started spending a lot of time on Zoom." Social experiences are important to health, so carving out time for this can improve your well-being. More specifically, reach out to loved ones who make you feel good about yourself since positive social interactions are linked to better coping and lower stress, research shows. If your schedule and circumstances allow for catching up in-person, aim for a spontaneous coffee meetup with a friend or accept your colleague's invitation to join their festivities. None of the plans have to be grand, orchestrated celebrations. The point is to connect with someone at some point during the holidays if possible. Volunteering, such as at a children's hospital or at a nursing home, can be beneficial for those spending this season alone. You can also find opportunities to serve meals at a soup kitchen or food bank in your community. Some locations could use the help to hand out food at a holiday meal pick-up center. "There's all sorts of structured activities that people can engage in when they're spending time with other people, even strangers, and they're doing something thoughtful and nice for them," Williams said. That kind of an activity can impact one's brain in a positive way. "If someone takes action, they get outside of themselves, then they're thinking about other people," Williams said. "People generally feel better when that happens." You might be missing only your grandma's mac-and-cheese or wishing you were baking pies for many to enjoy. It's common for holidays to evoke images of people gathering around a shared meal. If you're alone, try to cook something special, order takeout or order something delicious at a restaurant, Winston said. If you're going to be out of town on a work trip, research the best nearby restaurants to your liking and splurge on a nice dinner. If you're choosing to be a homebody this year, be as lazy or as complex as you'd like with the meal—if it nurtures you. Rituals and fun family routines around the holidays are an important part of celebrating and maybe what you are missing most this time of year. "Can they perform some ritual that punctuates the day and makes it feel special in some way?" Williams said. Taking a hot bath, getting a massage or playing a sport can be nurturing to some people, Winston said. Light the menorah, hang up a stocking on your fireplace, or do the New Year's Eve countdown for yourself. You can observe the days however you'd like without disagreements with others, judgment or the pressure of expectations. Having a sense of accomplishment, such as by working on a home project, during this solitary time can also be one way to get through the holidays, Winston said. "People can be creative about their use of their time," she said. Seasonal chores like raking leaves or shoveling snow, decorating your house or decluttering your closets can also count as functional exercise without hitting the gym. Another more introspective activity is to take advantage of the solitude to plan for the new year or review the past year. "Especially for (the) new year, people love to reflect on the previous year," Williams said. "And doing that in an intentional, structured way and even outlining the ways they want the new year to be different or even citing specific goals for the new year." Spend the holiday creating new traditions, like creating a vision board or reviewing the highs and lows of your year in a journal. Winston suggests coupling actions with a strong mental approach—a mindfulness perspective— to help one with loneliness feelings. "Paying attention to our present moment experiences with openness, curiosity and a willingness to be with that experience" is mindfulness, according to Winston. "It's really about learning to live in the present moment, not lost in the past or the future." Understandably, the willpower to focus only on the now and block out the other noise can be challenging, and fully accepting that present reality is key. When things look and feel different and when one is in a transition period, clinical psychologist Dr. Adam Brown previously told CNN that there is no requirement to have the holidays look or feel the same as they had in the past. "Be compassionate with yourself and do the best that you can and know that this is a particular moment in the year," Winston said. "There's nothing wrong with you and you will get through it." It's also helpful to remember that not all those who are spending their holidays surrounded by people are having a good time. "We have a lot of input, demands and stress in general that is elevated during the holidays, so it is extra important to be attentive to your need for alone time," Sophie Lazarus, a clinical psychologist in the department of psychiatry and behavioral health at Ohio State University told CNN earlier this month. Due to some last-minute logistical challenges last month, I was unable to spend Thanksgiving with my family. Even though I knew I would be able to fly home the next day, I was still bummed to miss my family traditions. To make the best of the situation, I did as many of my favorite things as I could: I walked around my neighborhood, read news magazines and sat for hours in a bustling coffee shop to write. To cap it off, I went to a special Thanksgiving dinner by myself at a local restaurant. I missed time with my family, but I would say I still had an experts-approved day. I highly recommend turning your day alone into a gratifying one, and even if you're not going to be alone, try to carve out time for yourself in the midst of social obligations to help keep you grounded and serene.One of the most notable trends in this year's nominations is the success of Netflix, which looks set to be a big winner at the upcoming awards ceremony. With a plethora of acclaimed series and films under its belt, Netflix has emerged as a major player in the entertainment industry, and its dominance is reflected in the nominations for the Golden Globes.
Jimmy Carter's legacy remembered in Central Illinois and beyond
( MENAFN - GetNews) (Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Peripheral T Cell Lymphomas pipeline constitutes 40+ key companies continuously working towards developing 40+ Peripheral T Cell Lymphomas treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Peripheral T Cell Lymphomas Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. “Peripheral T Cell Lymphomas Pipeline Insight, 2024 " report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Peripheral T Cell Lymphomas Market. Some of the key takeaways from the Peripheral T Cell Lymphomas Pipeline Report: Companies across the globe are diligently working toward developing novel Peripheral T Cell Lymphomas treatment therapies with a considerable amount of success over the years. Peripheral T Cell Lymphomas companies working in the treatment market are HUYA Bioscience International, Applied Therapeutics, Autolus, Akeso Biopharma, Astex Pharmaceuticals, Secura Bio, Innate Pharma, Dizal Pharmaceutical, CSPC ZhongQi Pharmaceutical Technology, and others , are developing therapies for the Peripheral T Cell Lymphomas treatment Emerging Peripheral T Cell Lymphomas therapies in the different phases of clinical trials are- HBI-8000, AT-104, Auto 5, AK 104, Tolinapant, Duvelisib, Lacutamab, AZD 4205, Mitoxantrone liposomal, and others are expected to have a significant impact on the Peripheral T Cell Lymphomas market in the coming years. In December 2024, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") announced new data showcasing significant improvements in quality of life for patients with cutaneous T-cell lymphoma (CTCL) treated with lacutamab in the TELLOMAK Phase 2 clinical study. The findings were presented at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego, California. In December 2024, Secura Bio, Inc. (Secura Bio), an integrated pharmaceutical company focused on the global development and commercialization of effective oncology therapies, presented two posters at the 2024 American Society of Hematology (ASH) Annual Meeting in San Diego, CA. The first poster showcased new data from the Company's Phase 2 PRIMO trial of duvelisib for treating relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL), while the second poster outlined the clinical design for the planned Phase 3 randomized trial of duvelisib in R/R nodal T-follicular helper cell lymphoma (TERZO). Peripheral T Cell Lymphomas Overview Peripheral T-cell lymphomas (PTCL) are a diverse group of aggressive blood cancers that develop in T-cells, a type of white blood cell involved in immune function. Unlike other types of lymphoma, PTCL originates outside the bone marrow, typically in lymph nodes, spleen, or other tissues. Symptoms may include swollen lymph nodes, fever, weight loss, night sweats, and skin rashes. PTCL is rare and often more difficult to treat compared to other lymphomas. Treatment options may include chemotherapy, immunotherapy, stem cell transplants, and targeted therapies, depending on the specific subtype and stage of the disease. Get a Free Sample PDF Report to know more about Peripheral T Cell Lymphomas Pipeline Therapeutic Assessment- Emerging Peripheral T Cell Lymphomas Drugs Under Different Phases of Clinical Development Include: HBI-8000: HUYA Bioscience International AT-104: Applied Therapeutics Auto 5: Autolus AK 104: Akeso Biopharma Tolinapant: Astex Pharmaceuticals Duvelisib: Secura Bio Lacutamab: Innate Pharma AZD 4205: Dizal Pharmaceutical Mitoxantrone liposomal: CSPC ZhongQi Pharmaceutical Technology Peripheral T Cell Lymphomas Route of Administration Peripheral T Cell Lymphomas pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as Subcutaneous Intravenous Oral Intramuscular Intra-tumoral Molecule Type Peripheral T Cell Lymphomas Molecule Type Peripheral T Cell Lymphomas Products have been categorized under various Molecule types, such as Monoclonal antibodies Immunoglobulins Small molecules Pyrimidines Proteins and Peptides Product Type Peripheral T Cell Lymphomas Pipeline Therapeutics Assessment Peripheral T Cell Lymphomas Assessment by Product Type Peripheral T Cell Lymphomas By Stage and Product Type Peripheral T Cell Lymphomas Assessment by Route of Administration Peripheral T Cell Lymphomas By Stage and Route of Administration Peripheral T Cell Lymphomas Assessment by Molecule Type Peripheral T Cell Lymphomas by Stage and Molecule Type DelveInsight's Peripheral T Cell Lymphomas Report covers around 40+ products under different phases of clinical development like Late-stage products (Phase III) Mid-stage products (Phase II) Early-stage product (Phase I) Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates Route of Administration Further Peripheral T Cell Lymphomas product details are provided in the report. Download the Peripheral T Cell Lymphomas pipeline report to learn more about the emerging Peripheral T Cell Lymphomas therapies Some of the key companies in the Peripheral T Cell Lymphomas Therapeutics Market include: Key companies developing therapies for Peripheral T Cell Lymphomas are - Celleron Therapeutics, Myeloid Therapeutics, Astex Pharmaceuticals, Citius Pharmaceuticals, Innate Pharma, Secura Bio, Genor Biopharma Co., Ltd., CerRx, Inc., Dizal Pharmaceuticals, Kura Oncology, Inc., Viracta Therapeutics, Autolus Therapeutics, Affimed Therapeutics, C4 Therapeutics, Kymera Therapeutics, Daiichi Sankyo, SciTech Development LLC, Sorrento Therapeutics, Bristol-Myers Squibb, Shanghai Yingli Pharmaceutical, Ono Pharmaceutical, and others. Peripheral T Cell Lymphomas Pipeline Analysis: The Peripheral T Cell Lymphomas pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Peripheral T Cell Lymphomas with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Peripheral T Cell Lymphomas Treatment. Peripheral T Cell Lymphomas key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Peripheral T Cell Lymphomas Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Peripheral T Cell Lymphomas market. The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. Download Sample PDF Report to know more about Peripheral T Cell Lymphomas drugs and therapies Peripheral T Cell Lymphomas Pipeline Market Drivers Increase in incidences of PTCL, rising investment for the development of advanced technologies, surge in government initiatives to promote research and awareness about the disease are some of the important factors that are fueling the Peripheral T Cell Lymphomas Market. Peripheral T Cell Lymphomas Pipeline Market Barriers However, high cost associated with the treatment, lack of skilled professionals for early diagnosis of the disease and other factors are creating obstacles in the Peripheral T Cell Lymphomas Market growth. Scope of Peripheral T Cell Lymphomas Pipeline Drug Insight Coverage: Global Key Peripheral T Cell Lymphomas Companies: HUYA Bioscience International, Applied Therapeutics, Autolus, Akeso Biopharma, Astex Pharmaceuticals, Secura Bio, Innate Pharma, Dizal Pharmaceutical, CSPC ZhongQi Pharmaceutical Technology, and others Key Peripheral T Cell Lymphomas Therapies: HBI-8000, AT-104, Auto 5, AK 104, Tolinapant, Duvelisib, Lacutamab, AZD 4205, Mitoxantrone liposomal, and others Peripheral T Cell Lymphomas Therapeutic Assessment: Peripheral T Cell Lymphomas current marketed and Peripheral T Cell Lymphomas emerging therapies Peripheral T Cell Lymphomas Market Dynamics: Peripheral T Cell Lymphomas market drivers and Peripheral T Cell Lymphomas market barriers Request for Sample PDF Report for Peripheral T Cell Lymphomas Pipeline Assessment and clinical trials Table of Contents 1. Peripheral T Cell Lymphomas Report Introduction 2. Peripheral T Cell Lymphomas Executive Summary 3. Peripheral T Cell Lymphomas Overview 4. Peripheral T Cell Lymphomas- Analytical Perspective In-depth Commercial Assessment 5. Peripheral T Cell Lymphomas Pipeline Therapeutics 6. Peripheral T Cell Lymphomas Late Stage Products (Phase II/III) 7. Peripheral T Cell Lymphomas Mid Stage Products (Phase II) 8. Peripheral T Cell Lymphomas Early Stage Products (Phase I) 9. Peripheral T Cell Lymphomas Preclinical Stage Products 10. Peripheral T Cell Lymphomas Therapeutics Assessment 11. Peripheral T Cell Lymphomas Inactive Products 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Peripheral T Cell Lymphomas Key Companies 14. Peripheral T Cell Lymphomas Key Products 15. Peripheral T Cell Lymphomas Unmet Needs 16 . Peripheral T Cell Lymphomas Market Drivers and Barriers 17. Peripheral T Cell Lymphomas Future Perspectives and Conclusion 18. Peripheral T Cell Lymphomas Analyst Views 19. Appendix 20. About DelveInsight About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. MENAFN23122024003238003268ID1109025437 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.